US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Pila Pharma broadens XEN-D0501 with new indication

During spring, Malmö-based Pila Pharma announced that they had applied for orphan drug designation for the drug candidate XEN-D0501 for the treatment of erythromelalgia. In mid-July, the company announced that the FDA had given the application the green light and with previous clinical findings as a base, the project can go straight into clinical phase II/III studies. BioStock contacted Pila Pharma’s CEO Dorte X. Gram to find out more about what the summer’s big news means for the company.Read the full article at biostock.se:https://www.biostock.se/en/2022/08/pila-pharma-broadens-xen-

BioStock: Pila Pharma’s CEO comments on the Q2 report

Malmö-based biotech company Pila Pharma advances towards clinical phase II studies with XEN-D0501 at a steady pace. During the second quarter of 2022 the company announced plans to enter a new indication with the drug candidate. BioStock asked the company’s CEO Dorte X. Gram about her views on the second quarter and about the plans ahead.Read the full article at biostock.se: https://www.biostock.se/en/2022/08/pila-pharmas-ceo-comments-on-the-q2-report/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Pila Pharma initiates toxicological studies

Malmö company Pila Pharma is in full swing with preparations for a phase IIb study with the drug candidate XEN-D0501. But before the study can initiated, the company needs to conduct a three-month preclinical toxicological study. The company has now announced that the toxicological study has started. BioStock contacted Pila Pharma’s CEO Dorte X Gram to find out more.Read the full article at biostock.se:https://www.biostock.se/en/2022/07/pila-pharma-initiates-toxicological-studies/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Deep dive into Pila Pharma’s clinical concept

Type 2 diabetes is one of the world’s most common diseases. A company that wants a piece of the diabetes market pie is Malmö-based Pila Pharma, which is currently conducting preclinical studies with its candidate XEN-D0501. BioStock has taken a closer look at the clinical concept that underpins Pila Pharma’s development.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/deep-dive-into-pila-pharmas-clinical-concept/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Pila Pharma takes XEN-D0501 into pain management

After focusing solely on diabetes as a development track for candidate XEN-D0501, Pila Pharma is now taking the next step of its journey filing an application for Orphan Drug Designation in the U.S. If this is approved, it will allow the company to expand its pipeline by adding a new indication. BioStock contacted CEO Dorte X. Gram to find out more about the venture and first quarter of the year.Read the full article at biostock.se:https://www.biostock.se/en/2022/04/pila-pharma-takes-xen-d0501-into-pain-management/This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Pila Pharma’s CEO on building the company since its IPO

“We’re on our way.” This is how Pila Pharma CEO Dorte X. Gram starts the 2021 year end report that was released last week. During the first half of the year as a public company, the focus has been on building the high-quality team that will drive the development of the drug candidate XEN-D0501, hopefully all the way to market. In connection with the newly released report, BioStock has contacted Gram to get her view of the past year.Read the full article at biostock.se:https://www.biostock.se/en/2022/02/pila-pharmas-ceo-on-building-the-company-since-its-ipo/This is a press release from

BioStock: Novo veteran strengthens Pila Pharma

Production of study material of XEN-D0501 is underway and is expected to be completed before the summer, whereupon Pila Pharma can start a three-month toxicology study with the drug candidate. In parallel with the study preparations, the company implements organizational changes and strengthens its team. Susanne Rugh, a long-time veteran of Novo Nordisk, is now taking over the role of project director for the diabetes program.Read the full article at biostock.se:https://www.biostock.se/en/2022/02/novo-veteran-strengthens-pila-pharma/This is a press release from BioStock - Connecting

BioStock: Several triggers for Pila Pharma in 2022

There is no doubt that type 2 diabetes has become one of the most common diseases with more than half a billion people affected, according to t International Diabetes Federation. Malmö company Pila Pharma with CEO Dorte X Gram develops a new approach, and, since July 2021, the company’s shares are listed on Nasdaq First North Growth Market. Several milestones have already been reached, and there will be several potential triggers for the stock in 2022.Read the full article at biostock.se:https://www.biostock.se/en/2022/01/several-triggers-for-pila-pharma-in-2022/This is a press release

BioStock: Pila Pharma enters agreement for toxicological studies

The journey towards phase IIb in type 2 diabetes continues for Malmö-based Pila Pharma. On Friday, the company announced that they had signed an agreement with the CRO ERBC to conduct three-month pre-clinical toxicology studies, a prerequisite to continue the clinical development.Read the full article at biostock.se:https://www.biostock.se/en/2021/11/pila-pharma-enters-agreement-for-toxicological-studiesThis is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Pila Pharma CEO increases holding

When Malmö-based Pila Pharma started trading on Nasdaq First North Growth Market barely six months ago, founder and CEO Dorte X. Gram first entered the world of the stock market. Now, a few months later, she has increased her holding in the company.Read the full article at biostock.se:https://www.biostock.se/en/2021/11/pila-pharma-ceo-increases-holding/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Pila Pharma rounds off first quarter as a publicly traded company

So far, 2021 has been a transformative year for Pila Pharma, and the third quarter was no exception. The company can look back at a period characterised by a publicly traded share, a scientific principle being awarded the Nobel Prize, and preparations for phase II. Shifting its focus on what lies ahead, additional milestones are coming up for Pila Pharma.Read the full article at biostock.se:https://www.biostock.se/en/2021/11/pila-pharma-rounds-off-first-quarter-as-a-publicly-traded-company/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Discovery behind Pila Pharma’s leading principle receives Nobel Prize

The 2021 Nobel Prize in Medicine went to David Julius and Ardem Patapoutian for their discoveries of the body’s receptors for temperature and touch. The principle behind the Nobel Laureates’ discovery can be found at the Malmö-based biotech company Pila Pharma, which has further researched the TRPV1 receptor to develop a treatment for type 2 diabetes. BioStock contacted the company’s CEO Dorte X Gram to get her view on the fact that the discoveries have now been awarded a Nobel Prize.Read the full article at biostock.se:https://www.biostock.se/en/2021/10/discovery-behind-pila-pharmas-

BioStock: Pila Pharma takes final steps before toxicology studies

After this summer’s IPO, Malmö-based Pila Pharma is at full activity, preparing for the upcoming phase IIb study with drug candidate XEN-D0501. In its latest reached milestone, the company has completed GMP production of placebo tablets that will be used in the study, and the next step is to implement the toxicology program. BioStock contacted the company’s founder and CEO Dorte X. Gram to learn more about what lies ahead.Read the full article at biostock.se:https://www.biostock.se/en/2021/09/pila-pharma-takes-final-steps-before-toxicology-studies/This is a press release from BioStock -

There are no items matching the current filter
There are no more items matching the current filter
Back to top